A basic peptide derived from the HARP C-terminus inhibits anchorage-independent growth of DU145 prostate cancer cells

被引:21
作者
Bermek, Oya
Diamantopoulou, Zoi
Polykratis, Apostolis
Dos Santos, Celia
Hamma-Kourbali, Yamina
Burlina, Fabienne
Delbe, Jean
Chassaing, Gerard
Fernig, David G.
Katsoris, Pagnagiotis
Courty, Jose
机构
[1] Univ Paris 12, CNRS, UMR 7149, CRRET, F-94010 Creteil, France
[2] Univ Patras, Dept Biol, Div Genet Cell & Dev Biol, GR-26504 Patras, Greece
[3] Univ Paris 06, CNRS, UMR 7613, Lab Synth Struct & Fonct Mol Bioact, F-75252 Paris, France
[4] Univ Liverpool, Sch Biol Sci, Liverpool L69 7ZB, Merseyside, England
关键词
heparin affin regulatory peptide; prostate cancer; anchorage-independent growth; basic peptide; receptor protein tyrosine; phosphatase;
D O I
10.1016/j.yexcr.2007.07.032
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
Heparin affin regulatory peptide (HARP) is an 18 kDa heparin-binding protein that plays a key role in tumor growth. We showed previously that the synthetic peptide P(111-136) composed of the last 26 HARP amino acids inhibited HARP-induced mitogenesis. Here, to identify the exact molecular domain involved in HARP inhibition, we investigated the effect of the shorter basic peptide P(122-131) on DU145 cells, which express HARP and its receptor protein tyrosine phosphatase beta/zeta (RPTP beta/zeta). P(122-131) was not cytotoxic; it dose-dependently inhibited anchorage-independent growth of DU145 cells. Binding studies using biotinylated P(122-131) indicated that this peptide interfered with HARP binding to DU145 cells. Investigation of the mechanisms involved suggested interference, under anchorage-independent conditions, of P(122-131) with a HARP autocrine loop in an RPTP beta/zeta dependent fashion. Thus, P(122-131) may hold potential for the treatment of disorders involving RPTP beta/zeta. (C) 2007 Elsevier Inc. All rights reserved.
引用
收藏
页码:4041 / 4050
页数:10
相关论文
共 38 条
[1]
Improved and simple micro assay for sulfated glycosaminoglycans quantification in biological extracts and its use in skin and muscle tissue studies [J].
Barbosa, I ;
Garcia, S ;
Barbier-Chassefière, V ;
Caruelle, JP ;
Martelly, I ;
Papy-García, D .
GLYCOBIOLOGY, 2003, 13 (09) :647-653
[2]
Dominant negative effectors of heparin affin regulatory peptide (HARP) angiogenic and transforming activities [J].
Bernard-Pierrot, I ;
Delbé, J ;
Rouet, V ;
Vigny, M ;
Kerros, ME ;
Caruelle, D ;
Raulais, D ;
Barritault, D ;
Courty, J ;
Milhiet, PE .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (35) :32071-32077
[3]
The lysine-rich C-terminal tail of heparin affin regulatory peptide is required for mitogenic and tumor formation activities [J].
Bernard-Pierrot, I ;
Delbé, J ;
Caruelle, D ;
Barritault, D ;
Courty, J ;
Milhiet, PE .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (15) :12228-12234
[4]
Effect of androgen deprivation therapy on prostatic intraepithelial neoplasia [J].
Bostwick, DG ;
Qian, JQ .
UROLOGY, 2001, 58 (2A) :91-93
[5]
PLEIOTROPHIN TRANSFORMS NIH 3T3 CELLS AND INDUCES TUMORS IN NUDE-MICE [J].
CHAUHAN, AK ;
LI, YS ;
DEUEL, TF .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (02) :679-682
[6]
Choudhuri R, 1997, CANCER RES, V57, P1814
[7]
MITOGENIC PROPERTIES OF A NEW ENDOTHELIAL-CELL GROWTH-FACTOR RELATED TO PLEIOTROPHIN [J].
COURTY, J ;
DAUCHEL, MC ;
CARUELLE, D ;
PERDERISET, M ;
BARRITAULT, D .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1991, 180 (01) :145-151
[8]
CZUBAYKO F, 1994, J BIOL CHEM, V269, P21358
[9]
Melanoma angiogenesis and metastasis modulated by ribozyme targeting of the secreted growth factor pleiotrophin [J].
Czubayko, F ;
Schulte, AM ;
Berchem, GJ ;
Wellstein, A .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (25) :14753-14758
[10]
DONG Z, 2002, SCI STKE, pPL7